Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one
2. Gdc-0853
1. Gdc-0853
2. 1434048-34-6
3. Rg7845
4. Gdc0853
5. Rg-7845
6. Fenebrutinib [inn]
7. Fenebrutinib [usan]
8. Ro7010939
9. E9l2885wul
10. (s)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one
11. Chembl4065122
12. G02599853
13. Ro-7010939
14. G-02599853
15. 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one
16. 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one
17. Fenebrutinib (usan/inn)
18. Fenebrutinib [usan:inn]
19. Unii-e9l2885wul
20. Fenebrutinib (gdc-0853)
21. Fenebrutinib [who-dd]
22. Gtpl9299
23. Schembl14912882
24. Bcp19175
25. Ex-a1308
26. Gdc 0853
27. Gdc-0853gdc-0853
28. Bdbm50244440
29. Nsc798202
30. S8421
31. Zinc220197997
32. Cs-5927
33. Db14785
34. Gdc-0853(rg7845)
35. Nsc-798202
36. Ac-32585
37. Bs-15120
38. Hy-19834
39. Rg-7845 (gdc-0853)
40. Example 130 [us20140194408]
41. J3.615.209e
42. A16339
43. D11457
44. A904370
45. Q23304817
46. (s)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl- 4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1h-cyclopenta (4,5)pyrrolo(1,2-a)pyrazin-1-one
47. 2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one
48. 2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one, 2-(1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-((5-((2s)-2-methyl-4-(3-oxetanyl)-1-piperazinyl)-2-pyridinyl)amino)-6-oxo(3,4'-bipyridin)-2'-yl)-3,4,7,8-tetrahydro-7,7-dimethyl-
49. 2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one, 2-(1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-((5-((2s)-2-methyl-4-(3-oxetanyl)-1-piperazinyl)-2-pyridinyl)amino)-6-oxo(3,4'-bipyridin)-2'-yl)3,4,7,8-tetrahydro-7,7-dimethyl-
50. 9aj
| Molecular Weight | 664.8 g/mol |
|---|---|
| Molecular Formula | C37H44N8O4 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 664.34855191 g/mol |
| Monoisotopic Mass | 664.34855191 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 1340 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of multiple sclerosis
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
56
PharmaCompass offers a list of Fenebrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fenebrutinib manufacturer or Fenebrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fenebrutinib manufacturer or Fenebrutinib supplier.
A RG-7845 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RG-7845, including repackagers and relabelers. The FDA regulates RG-7845 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RG-7845 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A RG-7845 supplier is an individual or a company that provides RG-7845 active pharmaceutical ingredient (API) or RG-7845 finished formulations upon request. The RG-7845 suppliers may include RG-7845 API manufacturers, exporters, distributors and traders.
RG-7845 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RG-7845 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right RG-7845 GMP manufacturer or RG-7845 GMP API supplier for your needs.
A RG-7845 CoA (Certificate of Analysis) is a formal document that attests to RG-7845's compliance with RG-7845 specifications and serves as a tool for batch-level quality control.
RG-7845 CoA mostly includes findings from lab analyses of a specific batch. For each RG-7845 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RG-7845 may be tested according to a variety of international standards, such as European Pharmacopoeia (RG-7845 EP), RG-7845 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RG-7845 USP).
